

- 56 Szebeni J, Barna K, Uher F, Milosevits J, Paloczi K, Gaal D, et al. *Leukemia* 1997;**11**:1769.
- 57 Coleman RS, Pérez RJ, Burk CH, Navarro A. *J Am Chem Soc* 2002;**124**:13008.
- 58 Foulke-Abel J, Agbo H, Zhang H, Mori S, Watanabe CMH. *Nat Prod Rep* 2011;**28**:693.
- 59 Ravdin PM, Havlin KA, Marshall MV, Brown TD, Koeller JM, Kuhn JG, et al. *Cancer Res* 1991;**51**:6268.
- 60 Bedford P, Fox BW. *Biochem Pharmacol* 1983;**32**:2297.
- 61 Hartley JA, O'Hare CC, Baumgart J. *Br J Cancer* 1999;**79**:264.
- 62 Iwamoto T, Hiraku Y, Oikawa S, Mizutanei H, Kojima M, Kawanishi S. *Cancer Res* 2004;**95**:454.
- 63 Farmer PB. *Pharmacol Ther* 1987;**35**:301.
- 64 Puppa AD, Rossetto M, Ciccarino P, Denaro L, Rotilio A, d'Avella D, et al. *World Neurosurg* 2011;**76**:156.
- 65 Glas M, Hundsberger T, Stuplich M, Wiewrodt D, Kurzwelly D, Nguyen-Huu B, et al. *Oncology* 2009;**76**:174.
- 66 Samson MK, Baker LH, Cummings G, Talley RW, McDonald B, Bhatena DB. *Cancer Treat Rep* 1982;**66**:371.
- 67 Hayes MT, Bartley J, Parsons PG, Eaglesham GK, Prakask AS. *Biochemistry* 1997;**36**:10646.
- 68 Montgomery JA, James R, McCaleb GS, Johnston TP. *J Med Chem* 1967;**10**:668.
- 69 Johnston TP, Montgomery JA. *Cancer Treat Rep* 1986;**70**:13.
- 70 Buckley N. *J Org Chem* 1987;**52**:484.
- 71 Murata M, Takahashi A, Saito I, Kawanishi S. *Biochem Pharmacol* 1999;**57**:881.
- 72 Bolzán AD, Bianchi MS. *Mutat Res* 2002;**512**:121.
- 73 Kroncke KD, Fehsel K, Sommer A, Rodriguez ML, Kolb-Bachofen V. *Biol Chem Hoppe Seyler* 1995;**376**:179.
- 74 Bedoya FJ, Solano F, Lucas M. *Experientia* 1996;**52**:344.
- 75 García del Muro X, López-Pousa A, Maurel J, Martín J, Martínez-Trufero J, Casado A, et al. *J Clin Oncol* 2011;**29**:2528.
- 76 Meer L, Janzer RC, Kleihues P, Kolar GF. *Biochem Pharmacol* 1986;**35**:3243.
- 77 Kyrtopoulos SA, Souliotis VL, Valavanis C, Boussiotis VA, Pangalis GA. *Environ Health Perspect* 1993;**99**:143.
- 78 Glaser R, Sik-Cheung Choy G, Kirk Hall M. *J Am Chem Soc* 1991;**113**:1109.
- 79 For a review of temozolomide development, see Stevens MFG. In: Neidle S, editor. *Cancer drug design and discovery*. 2nd ed. New York: Elsevier; 2014 [chapter 5].
- 80 Fukushima T, Takeshima H, Kataoka H. *Anticancer Res* 2009;**29**:4845.
- 81 Renschler MF, Eur J. *Cancer* 2004;**40**:1934.
- 82 Chan JK, Loizzi V, Manetta A, Berman ML. *Gynecol Oncol* 2004;**92**:368.
- 83 Ames MM. *Cancer Treat Rev* 1991;**18**(Suppl. A):3.
- 84 Jackso C, Crabb TA, Gibson M, Godfrey R, Saunders R, Thurston DE. *J Pharm Sci* 1991;**80**:245.
- 85 Coley HM, Brooks N, Phillips DH, Hewer A, Jenkins TC, Jarman M, et al. *Biochem Pharmacol* 1995;**11**:1203.
- 86 Judson IR, Calvert AH, Gore ME, Balmanno K, Gumbrell LA, Perren T, et al. *Br J Cancer* 1991;**63**:311.
- 87 Kehe K, Szinicz L. *Toxicology* 2005;**214**:198.
- 88 Reedijk J, Eur J. *Inorg Chem* 2009;**2009**:130.
- 89 Lippard SJ. *Pure Appl Chem* 1987;**59**:731.
- 90 Takahara PM, Rosenzweig AC, Frederick CA, Lippard SJ. *Nature* 1995;**377**:649.
- 91 Ohndorf U, Rould MA, He Q, Pabo CO, Lippard SJ. *Nature* 1999;**399**:708.
- 92 Huang H, Zhu L, Reid BR, Drobny GP, Hopkins PB. *Science* 1995;**270**:1842.
- 93 Dong W, Lippard SJ. *Nature Rev Drug Discov* 2005;**4**:307.
- 94 Rebillard A, Lagadic-Gossmann D, Dimanche-Boitrel M-T. *Curr Med Chem* 2008;**15**:2656.
- 95 Sheikh-Hamad D, Am J. *Physiol* 2008;**295**:F42.
- 96 Monneret C. *Ann Pharm Fr* 2011;**69**:286.
- 97 For a review of the status of platinum anticancer drugs in the clinic and in clinical trials, see Wheate NJ, Walker S, Craig GE, Oun R. *Dalton Trans* 2010;**39**:8113.